Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AB Science Gelecekteki Büyüme

Future kriter kontrolleri 1/6

AB Science's earnings are forecast to decline at 8.6% per annum while its annual revenue is expected to grow at 7.2% per year. EPS is expected to decline by 13.4% per annum.

Anahtar bilgiler

-8.6%

Kazanç büyüme oranı

-13.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.7%
Gelir büyüme oranı	7.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	14 Mar 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

If You Had Bought AB Science (EPA:AB) Stock A Year Ago, You Could Pocket A 90% Gain Today

Feb 14

What Kind Of Shareholders Hold The Majority In AB Science S.A.'s (EPA:AB) Shares?

Dec 22

Our Take On AB Science's (EPA:AB) CEO Salary

Nov 17

Kazanç ve Gelir Büyüme Tahminleri

ENXTPA:AB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1	-17	-20	-19	1
12/31/2025	1	-18	-19	-18	1
12/31/2024	1	-19	-18	-18	1
12/31/2023	1	-12	-17	-17	N/A
9/30/2023	1	-14	N/A	N/A	N/A
6/30/2023	1	-17	-19	-18	N/A
3/31/2023	1	-15	-18	-18	N/A
12/31/2022	1	-14	-18	-17	N/A
9/30/2022	1	-15	N/A	N/A	N/A
6/30/2022	1	-17	-18	-17	N/A
3/31/2022	2	-16	-18	-17	N/A
12/31/2021	2	-14	-18	-17	N/A
9/30/2021	2	-13	-16	-16	N/A
6/30/2021	2	-11	-15	-14	N/A
3/31/2021	2	-13	-14	-14	N/A
12/31/2020	2	-15	-14	-14	N/A
9/30/2020	2	-16	-13	-13	N/A
6/30/2020	2	-18	-12	-12	N/A
3/31/2020	2	-20	-14	-14	N/A
12/31/2019	2	-22	-16	-15	N/A
9/30/2019	2	-25	-18	-18	N/A
6/30/2019	2	-28	-21	-20	N/A
3/31/2019	2	-27	-24	-23	N/A
12/31/2018	2	-26	-27	-27	N/A
9/30/2018	2	-25	-28	-27	N/A
6/30/2018	2	-25	-28	-28	N/A
3/31/2018	2	-26	-26	-25	N/A
12/31/2017	2	-27	-23	-23	N/A
9/30/2017	2	-27	N/A	-26	N/A
6/30/2017	2	-26	N/A	-28	N/A
3/31/2017	2	-27	N/A	-31	N/A
12/31/2016	2	-28	N/A	-34	N/A
9/30/2016	2	-28	N/A	-31	N/A
6/30/2016	2	-28	N/A	-28	N/A
3/31/2016	2	-28	N/A	-26	N/A
12/31/2015	2	-27	N/A	-23	N/A
9/30/2015	2	-24	N/A	-22	N/A
6/30/2015	2	-22	N/A	-21	N/A
3/31/2015	2	-19	N/A	-17	N/A
12/31/2014	2	-16	N/A	-14	N/A
9/30/2014	2	-16	N/A	-13	N/A
6/30/2014	2	-15	N/A	-12	N/A
3/31/2014	2	-15	N/A	-12	N/A
12/31/2013	2	-15	N/A	-13	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AB is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: AB is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: AB is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: AB's revenue (7.2% per year) is forecast to grow faster than the French market (5.7% per year).

Yüksek Büyüme Geliri: AB's revenue (7.2% per year) is forecast to grow slower than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if AB's Return on Equity is forecast to be high in 3 years time

AB Science Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 27% to €6.90

Price target increased to €23.11

Recent updates

AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19

Insufficient new directors

New minor risk - Market cap size

AB Science S.A., Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released

New minor risk - Financial data availability

AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS

Price target decreased by 27% to €6.90

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Shareholder dilution

AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

AB Science S.A. Receives Approval from the U.S. Food and Drug Administration (FDA) to Initiate the Confirmatory Phase 3 Study with Masitinib in the Treatment of Progressive Multiple Sclerosis

AB Science S.A. announced that it expects to receive €15 million in funding from European Investment Bank, Investment Arm

AB Science SA Receives Notice of Deficiency from Health Canada for Masitinib in Treatment of Amyotrophic Lateral Sclerosis

AB Science SA Receives U.S. Food and Drug Administration Authorization to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer’s Disease

AB Science Sa Receives First Agencies Authorizations to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer's Disease

First half 2022 earnings released: EPS: €0 (vs €0.099 loss in 1H 2021)

AB Science SA Announces Positive Recommendation of Data and Safety Monitoring Board to Continue Phase 2 Study Evaluating Antiviral Activity of Masitinib in Covid-19

AB Science Announces That It Has Filed an Application for Conditional Marketing Authorization to EMA for Masitinib in the Treatment of ALS

AB Science SA Announces Publication of Results from its Positive Study of Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids in the Peer-Reviewed Journal of Asthma and Allergy

AB Science Announces Changes in the Board of Directors

AB Science S.A. Announces Publication of Results from Its Positive Pivotal Phase 3 Trial of Masitinib in Progressive Forms of Multiple Sclerosis in the Peer-Reviewed Journal Neurology® Neuroimmunology & Neuroinflammation

AB Science SA Announces Health Canada Has Granted Authorization to File New Drug Submission for Masitinib in the Treatment of ALS Under the Notice of Compliance with Conditions (NOC/c) Policy

AB Science SA Grants Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the Swedish Medical Products Agency

AB Science SA Receives Authorization to Initiate Phase II Study in Patients with Severe Mast Cell Activation Syndrome by the French Health Authority (ANSM)

AB Science Announces That It Has Been Granted Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the French Health Authority (ANSM)

AB Science S.A. Announces Dosing of First Patient in Phase 2 Trial of Masitinib’s Antiviral Activity Against the SARS-CoV-2 (Covid-19) Virus

AB Science Receives FDA Authorization to Initiate Phase 1/Ii Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia

First half 2021 earnings released: €0.099 loss per share (vs €0.23 loss in 1H 2020)

AB Science SA Receives Regulatory Authorization to Commence A Second Phase 2 Covid-19 Study

AB Science S.A. Receives Health Canada Approval Letter to Commence Phase I/II Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia (AML)

AB Science S.A. Receives Authorization to Resume Patient Enrollment in the Phase 2 Masitinib Study of Covid-19

AB Science S.A. Receives New Authorizations to Resume Patient Enrollment in Its Phase 3 Studies of Masitinib

AB Science Announces Results from Masitinib Study Ab12003 in Prostate Cancer Have Been Presented At the 2021 American Urological Association

AB Science SA Announces That It Has Received Second Authorization to Resume Patient Enrollment, in the Phase 3 Study of Masitinib in Mastocytosis

AB Science Announces Receives the First Authorization to Resume Patient Enrollment in the Confirmatory Phase 3 Study of Masitinib (AB19001) in ALS

Price target increased to €23.11

AB Science Announces the Validation of Its Risk Management Plan by the French National Agency (ANSM) in Order to Restart Patient Enrollment in France

AB Science SA Announces Results from Masitinib Study AB12005 in Pancreatic Cancer Have Been Presented At the 2021 Asco Annual Meeting

AB Science SA Announces Update of Masitinib

AB Science SA Communicates Results from Phase 3 Study Evaluating Masitinib in Prostate Cancer

AB Science Sa Announces Results from Masitinib Study AB12005 in Pancreatic Cancer, Have Been Selected for Presentation at the Upcoming Asco Annual Meeting

Full year 2020 earnings released

AB Science Sa Announces Identification of Two Tissue Biomarkers That Could Potentially Serve as Predictive Biomarkers of Response for Masitinib Treatment

If You Had Bought AB Science (EPA:AB) Stock A Year Ago, You Could Pocket A 90% Gain Today

AB Science Announces a New Independent Publication Confirms That Masitinib Has Anti-Vital Activity Against the SARS-CoV-2 Virus in Vitro and Is A Promising Candidate for Treating COVID-19

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €10.50001 million.

What Kind Of Shareholders Hold The Majority In AB Science S.A.'s (EPA:AB) Shares?

AB Science Issues A Corrective Press Release Regarding Adverse Events Information from Study AB09004 Reported on December 16, 2020

AB Science Announces That Phase 2B/3 Study Evaluating Oral in Alzheimer’S Disease Met Its Primary Endpoint

New 90-day high: €14.34

AB Science S.A. Announces That Confirmatory Phase 3 Study AB12005 with Masitinib in First Line Pancreatic Cancer with Pain Was Successful

Our Take On AB Science's (EPA:AB) CEO Salary

AB Science S.A. Announces Results from masitinib Study AB07015 in Severe Asthma Have Been Selected for Presentation At an ATS Symposium Held on October 16, 2020

First half earnings released

AB Science SA Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Large Multiple Sclerosis Research Conference

New 90-day high - €12.58

New 90-day high - €9.50

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin